{"id":31162,"date":"2025-02-28T17:30:00","date_gmt":"2025-02-28T12:00:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31162"},"modified":"2025-09-10T10:47:15","modified_gmt":"2025-09-10T05:17:15","slug":"major-depressive-disorder-drugs-to-watch","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch","title":{"rendered":"7 Game-Changing Major Depressive Disorder Drugs in Development"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d03ea154dfe\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d03ea154dfe\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\/#7_Promising_Major_Depressive_Disorder_Drugs_to_Look_Out\" >7 Promising Major Depressive Disorder Drugs to Look Out<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\/#COMPASS_Pathways_COMP360\" >COMPASS Pathways\u2019 COMP360<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\/#SAGE_Therapeutics_and_Biogens_Zuranolone\" >SAGE Therapeutics and Biogen\u2019s Zuranolone&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\/#Luye_Pharmas_LY03005\" >Luye Pharma\u2019s LY03005&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\/#Minerva_Neurosciences_and_Janssen_Pharmaceuticals_Seltorexant\" >Minerva Neurosciences and Janssen Pharmaceutical\u2019s Seltorexant&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\/#Relmada_Therapeutics_REL-1017\" >Relmada Therapeutics\u2019 REL-1017<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\/#ABVC_BioPharmas_ABV-1504\" >ABVC BioPharma\u2019s ABV-1504<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\/#VistaGen_Therapeutics_Itruvone\" >VistaGen Therapeutics\u2019 Itruvone<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\/#A_New_Era_in_Major_Depressive_Disorder_Treatment\" >A New Era in Major Depressive Disorder Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>The <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market\" class=\"ek-link\">Major Depressi<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market\" class=\"ek-link\"><strong>ve Disorder drug treatment market<\/strong><\/a> is expanding rapidly due to the increasing demand for antidepressants and the disease\u2019s profound impact on quality of life. In 2023, the major depressive disorder market across the 7MM was valued at an impressive <strong>USD 7.2 billion,<\/strong> and it\u2019s poised for even greater expansion, with exciting growth on the horizon through 2034. The major depressive disorder treatment landscape has seen significant advancements, with multiple approved therapies playing a crucial role in symptom management. Currently, widely prescribed <strong>drugs for MDD<\/strong> include <strong>AbbVie and Gedeon Richter\u2019s VRAYLAR, Axsome Therapeutics\u2019 AUVELITY, Johnson &amp; Johnson\u2019s SPRAVATO, Otsuka\u2019s REXULTI, and others<\/strong>. Regulatory agencies like the US FDA and the European Commission<strong> <\/strong>have accelerated approvals of innovative major depressive disorder therapies, further driving market growth.<\/p>\n\n\n\n<p>VRAYLAR, marketed by AbbVie and Gedeon Richter, is one of the leading treatments. AUVELITY, an innovative oral therapy developed by Axsome Therapeutics, offers a fast-acting approach. Trintellix from Takeda, SPRAVATO from Johnson &amp; Johnson, and REXULTI from Otsuka are also key therapies in the treatment landscape. Additionally, Fetzima from Forest Laboratories is another important option for patients.<\/p>\n\n\n\n<p>The market for major depressive disorder therapeutics in Europe is significant, with TRINTELLIX and SPRAVATO being widely prescribed treatments. In <strong>Jan 2025,<\/strong> the FDA approved <strong>SPRAVATO<\/strong> for use as a standalone treatment for adults with <strong><em>treatment-resistant depression<\/em><\/strong>. In Japan, approved therapies include <strong>TRINTELLIX and REXULTI<\/strong>, among others. Among various drug classes, Selective Serotonin Reuptake Inhibitors (SSRIs) dominate the major depressive disorder drugs market, given their long-standing effectiveness in managing depression. However, newer drug classes, such as Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Atypical Antipsychotics, are also making strides in improving treatment outcomes.<\/p>\n\n\n\n<p><strong><em>To learn more about SPRAVATO, <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/spravato-for-treatment-resistant-depression\"><strong><em>dive into our latest blog<\/em><\/strong><\/a><strong><em> crafted just for you!<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-7-promising-major-depressive-disorder-drugs-to-look-out\"><span class=\"ez-toc-section\" id=\"7_Promising_Major_Depressive_Disorder_Drugs_to_Look_Out\"><\/span>7 Promising Major Depressive Disorder Drugs to Look Out<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>While current <a href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-pipeline-insight\"><strong>major depressive disorder treatments<\/strong><\/a> have improved patient outcomes, many individuals still struggle with treatment-resistant depression or experience unwanted side effects. To address these challenges, several promising drugs are in development, aiming to transform the <a href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-treatment-outlook\"><strong>major depressive disorder pipeline<\/strong><\/a>. Among the most anticipated therapies are <strong>COMPASS Pathways\u2019 COMP360, SAGE Therapeutics and Biogen\u2019s Zuranolone, Luye Pharma\u2019s LY03005, Relmada Therapeutics\u2019 REL-1017, Minerva Neurosciences and Janssen Pharmaceutical\u2019s seltorexant, and BioLite and ABVC BioPharma\u2019s ABV-1504,<\/strong> among others.&nbsp;<\/p>\n\n\n\n<p>Let\u2019s get into the details of these major depressive disorder drugs and explore their mechanisms of action, clinical progress, and potential impact on the major depressive disorder therapeutics market. With ongoing research and clinical trials, these therapies hold the promise of reshaping major depressive disorder treatment, offering new hope to patients worldwide.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-compass-pathways-comp360\"><span class=\"ez-toc-section\" id=\"COMPASS_Pathways_COMP360\"><\/span>COMPASS Pathways\u2019 COMP360<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Phase &#8211; III<\/strong><\/p>\n\n\n\n<p>COMPASS Pathways is investigating its psilocybin-based therapy, COMP360, as a potential treatment for major depressive disorder and other serious mental health conditions. COMP360 is a synthetic formulation of psilocybin, administered with psychological support to enhance therapeutic outcomes. Psilocybin, the active compound found in certain \u201cmagic mushrooms,\u201d has demonstrated promising antidepressant effects in clinical research. COMP360 has received Breakthrough Therapy Designation from the US FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).&nbsp;<\/p>\n\n\n\n<p>In November 2022, findings from a Phase IIb study on COMP360\u2019s investigational psilocybin treatment were published in the New England Journal of Medicine. More recently, in April 2024, COMPASS Pathways and Journey Clinical announced a research collaboration aimed at developing a scalable delivery model and healthcare provider training program for COMP360. The company is also advancing a Phase II trial for MDD, while a Phase III trial is currently underway in partnership with Massachusetts General Hospital, further exploring COMP360\u2019s potential in addressing unmet needs in depression treatment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-sage-therapeutics-and-biogen-s-zuranolone-nbsp\"><span class=\"ez-toc-section\" id=\"SAGE_Therapeutics_and_Biogens_Zuranolone\"><\/span>SAGE Therapeutics and Biogen\u2019s Zuranolone&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Phase &#8211; III<\/strong><\/p>\n\n\n\n<p>Zuranolone, developed by SAGE Therapeutics and Biogen, is a next-generation oral positive allosteric modulator designed for major depressive disorder treatment. It is a highly potent and selective compound that targets synaptic and extrasynaptic GABAA receptors, with binding sites distinct from those of GABA, benzodiazepines, and barbiturates. As the GABA system plays a crucial role in regulating CNS function, zuranolone\u2019s mechanism offers a novel approach to treating MDD.&nbsp;<\/p>\n\n\n\n<p>Currently in Phase III clinical development, it is being evaluated through the LANDSCAPE and NEST clinical trial programs, which include multiple studies assessing various dosing regimens, clinical endpoints, and treatment strategies in thousands of patients. In February 2023, the US FDA accepted the New Drug Application (NDA) for zuranolone as an MDD treatment. Under a collaboration agreement, Shionogi holds the rights to development and commercialization in Japan and selects other countries. However, in August 2023, the FDA issued a Complete Response Letter (CRL) for the NDA, prompting Sage and Biogen to review the feedback and evaluate their next steps in advancing the drug within the major depressive disorder therapeutics market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-luye-pharma-s-ly03005-nbsp\"><span class=\"ez-toc-section\" id=\"Luye_Pharmas_LY03005\"><\/span>Luye Pharma\u2019s LY03005&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Phase &#8211; III&nbsp;<\/strong><\/p>\n\n\n\n<p>LY03005, developed by Luye Pharma, is a key product in the company\u2019s CNS therapeutic pipeline. It is an extended-release formulation of ansofaxine hydrochloride, a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI) designed for major depressive disorder treatment. By targeting the reuptake of dopamine, serotonin, and norepinephrine, LY03005 aims to provide enhanced efficacy and fewer side effects compared to traditional SSRIs and SNRIs. As a prodrug of desvenlafaxine, it has demonstrated superior efficacy in clinical trials. In March 2020, Luye Pharma announced that the US FDA had reviewed and accepted the NDA filing for LY03005, marking a significant step in its development within the major depressive disorder therapeutics market.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"572\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162453\/03-Intext-Image-4-Major-Depressive-Disorder-01-2-1024x572.jpg\" alt=\"Major Depressive Disorder pipeline \" class=\"wp-image-31170\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162453\/03-Intext-Image-4-Major-Depressive-Disorder-01-2-1024x572.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162453\/03-Intext-Image-4-Major-Depressive-Disorder-01-2-300x168.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162453\/03-Intext-Image-4-Major-Depressive-Disorder-01-2-150x84.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162453\/03-Intext-Image-4-Major-Depressive-Disorder-01-2-768x429.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162453\/03-Intext-Image-4-Major-Depressive-Disorder-01-2.jpg 1278w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-minerva-neurosciences-and-janssen-pharmaceutical-s-seltorexant-nbsp\"><span class=\"ez-toc-section\" id=\"Minerva_Neurosciences_and_Janssen_Pharmaceuticals_Seltorexant\"><\/span>Minerva Neurosciences and Janssen Pharmaceutical\u2019s Seltorexant&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Phase &#8211; III&nbsp;<\/strong><\/p>\n\n\n\n<p>Seltorexant, developed by Minerva Neurosciences and Janssen Pharmaceutical, is a selective orexin-2 receptor (ORX2) antagonist designed as an adjunctive therapy for MDD\u200b. It is the most advanced ORX2-targeting molecule in clinical development, working by blocking orexin-2 receptors to enhance its antidepressant effects. In January 2021, Royalty Pharma acquired Minerva\u2019s royalty interest in seltorexant for an upfront payment of USD 60 million, with the potential for up to USD 95 million in milestone payments. In certain indications, Minerva Neurosciences opted out of its joint development agreement with Janssen in 2020, retaining rights to mid-single-digit royalties on future global sales. In May 2024, Johnson &amp; Johnson announced positive topline results from the pivotal Phase III MDD3001 trial, evaluating seltorexant as an adjunctive major depressive disorder treatment alongside baseline antidepressants in adults and elderly patients. These findings were presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, highlighting the drug\u2019s potential in the major depressive disorder therapeutics market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-relmada-therapeutics-rel-1017\"><span class=\"ez-toc-section\" id=\"Relmada_Therapeutics_REL-1017\"><\/span>Relmada Therapeutics\u2019 REL-1017<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Phase &#8211; III<\/strong><\/p>\n\n\n\n<p>REL-1017, developed by Relmada Therapeutics, is a new chemical entity (NCE) and a novel NMDA receptor (NMDAR) channel blocker designed to target hyperactive channels while preserving normal glutamatergic neurotransmission selectively. Recognized for its potential in major depressive disorder treatment, REL-1017 has received Fast Track Designation from the US FDA. In Phase II trials, the drug demonstrated rapid, robust, and sustained antidepressant effects, showing statistically significant improvements over placebo while maintaining a favorable safety, tolerability, and pharmacokinetics profile.&nbsp;<\/p>\n\n\n\n<p>Currently, in late-stage development, REL-1017 is being evaluated in Phase III clinical trials as both an adjunctive and monotherapy for MDD treatment. However, in December 2024, Relmada Therapeutics announced the discontinuation of the Reliance II and Relight Phase III studies following a full dataset evaluation by the Data Monitoring Committee (DMC), despite previously published clinical data from the Reliance I Study in June 2024.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-abvc-biopharma-s-abv-1504\"><span class=\"ez-toc-section\" id=\"ABVC_BioPharmas_ABV-1504\"><\/span>ABVC BioPharma\u2019s ABV-1504<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Phase &#8211; II<\/strong><\/p>\n\n\n\n<p>ABV-1504, developed by ABVC BioPharma, is a botanical investigational new drug containing PDC-1421 as its active ingredient. Through its subsidiary BioLite, ABVC has completed a Phase II clinical trial evaluating ABV-1504 as a <a href=\"https:\/\/www.delveinsight.com\/report-store\/noradrenaline-transporter-nat-or-norepinephrine-transporter-or-net-inhibitor-pipeline-insight\">Norepinephrine Transporter (NET) inhibitor<\/a> for the treatment of major depressive disorder. The study at Stanford University confirmed that the PDC-1421 capsule was safe and well-tolerated, with low and high doses achieving the required 40% improvement in ADHD-RS-IV test scores.&nbsp;<\/p>\n\n\n\n<p>In April 2023, PDC-1421 received a US Patent (US 11,554,154 B2) for its use in MDD treatment. Having successfully completed Phase II trials in major depressive disorder patients, ABVC BioPharma now plans to initiate an End of Phase II (EOP II) meeting with the FDA to advance the drug\u2019s clinical development.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-vistagen-therapeutics-itruvone\"><span class=\"ez-toc-section\" id=\"VistaGen_Therapeutics_Itruvone\"><\/span>VistaGen Therapeutics\u2019 Itruvone<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Phase &#8211; II<\/strong><\/p>\n\n\n\n<p>Itruvone (PH10), developed by VistaGen Therapeutics, is an investigational first-in-class, fast-acting synthetic neurosteroid designed to address neuropsychiatric conditions associated with depression and suicidal ideation. VistaGen is initially advancing PH10 as a next-generation major depressive disorder treatment, offering a non-sedating, non-addictive, and self-administered alternative for patients. Administered as a nasal spray, PH10 delivers a microgram-level, non-systemic dose that activates nasal chemosensory receptors, triggering neural circuits in the brain to produce rapid antidepressant effects.&nbsp;<\/p>\n\n\n\n<p>Unlike traditional major depressive disorder drugs, PH10 avoids systemic exposure and potential side effects linked to oral antidepressants and esketamine-based therapies. Having successfully completed Phase IIa trials, VistaGen is preparing for Phase IIb clinical development of PH10 for MDD treatment. Notably, in December 2022, the US FDA granted PH10 Fast Track designation, further accelerating its clinical advancement.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-new-era-in-major-depressive-disorder-treatment\"><span class=\"ez-toc-section\" id=\"A_New_Era_in_Major_Depressive_Disorder_Treatment\"><\/span>A New Era in Major Depressive Disorder Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>With the number of <a href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-epidemiology-forecast\"><strong><em>Major Depressive Disorder cases rising<\/em><\/strong><\/a>\u2014the demand for innovative treatments has never been greater. The landscape of MDD treatment is evolving rapidly, with groundbreaking innovations in drug development offering new hope to patients worldwide. While traditional antidepressants like SSRIs and SNRIs remain widely used, the growing need for faster-acting, more effective, and well-tolerated therapies has driven pharmaceutical companies to explore novel mechanisms of action.<\/p>\n\n\n\n<p>The emergence of next-generation treatments highlights the shift towards precision medicine and targeted therapies, addressing key challenges such as treatment-resistant depression, delayed onset of action, and adverse side effects. These advancements signal a transformative period in MDD therapeutics, where innovative approaches are reshaping the standard of care.<\/p>\n\n\n\n<p>Beyond the drugs highlighted, numerous pharmaceutical companies\u2014including <strong>Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research &amp; Development, Axsome Therapeutics, AbbVie, Praxis Precision Medicines, Chase Therapeutics, Neumora Therapeutics, BlackThorn Therapeutics, Fabre-Kramer Pharmaceuticals, Novartis, and many others<\/strong>\u2014are actively driving innovation in the field.<\/p>\n\n\n\n<p>With <strong>ongoing clinical trials, regulatory advancements, and increasing investments <\/strong>in mental health drug development, the future of MDD treatment looks promising. As these therapies progress through clinical and regulatory milestones, they have the potential to provide millions of patients worldwide with more effective, personalized, and accessible treatment options, offering a brighter path out of the fog of depression.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28161243\/Major-Depressive-Disorder-Market-Outlook-and-Assessment--1024x194.png\" alt=\"Major Depressive Disorder market outlook\" class=\"wp-image-31168\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28161243\/Major-Depressive-Disorder-Market-Outlook-and-Assessment--1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28161243\/Major-Depressive-Disorder-Market-Outlook-and-Assessment--300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28161243\/Major-Depressive-Disorder-Market-Outlook-and-Assessment--150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28161243\/Major-Depressive-Disorder-Market-Outlook-and-Assessment--768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28161243\/Major-Depressive-Disorder-Market-Outlook-and-Assessment--1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28161243\/Major-Depressive-Disorder-Market-Outlook-and-Assessment-.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span>FAQs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1757481400469\"><strong class=\"schema-faq-question\"><strong>What are the FDA-approved drugs for major depressive disorder available in the market?<\/strong><\/strong> <p class=\"schema-faq-answer\">Currently, widely prescribed drugs for MDD include AbbVie and Gedeon Richter\u2019s VRAYLAR, Axsome Therapeutics\u2019 AUVELITY, Johnson &amp; Johnson\u2019s SPRAVATO, Otsuka\u2019s REXULTI, and others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757481407220\"><strong class=\"schema-faq-question\"><strong>Where is the major depressive disorder market headed?<\/strong><\/strong> <p class=\"schema-faq-answer\">In 2023, the major depressive disorder market across the 7MM was valued at an impressive USD 7.2 billion, and it\u2019s poised for even greater expansion, with exciting growth on the horizon through 2034.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757481421600\"><strong class=\"schema-faq-question\"><strong>What are the top 7 MDD drugs expected to change the market in the coming years?<\/strong><\/strong> <p class=\"schema-faq-answer\">The promising 7 MDD drugs in clinical trials include COMPASS Pathways\u2019 COMP360, SAGE Therapeutics and Biogen\u2019s Zuranolone, Luye Pharma\u2019s LY03005, Relmada Therapeutics\u2019 REL-1017, Minerva Neurosciences and Janssen Pharmaceutical\u2019s seltorexant, and BioLite and ABVC BioPharma\u2019s ABV-1504, among others.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Major Depressive Disorder drug treatment market is expanding rapidly due to the increasing demand for antidepressants and the disease\u2019s profound impact on quality of life. In 2023, the major depressive disorder market across the 7MM was valued at an impressive USD 7.2 billion, and it\u2019s poised for even greater expansion, with exciting growth on [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":31171,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[704,16942,19663,18806,19451,19450,19452,18539],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-31162","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-fda","tag-major-depressive-disorder","tag-major-depressive-disorder-mdd","tag-major-depressive-disorder-market","tag-major-depressive-disorder-therapies","tag-major-depressive-disorder-treatment","tag-mdd","tag-spravato","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>7 Emerging Major Depressive Disorder Drugs To Watch<\/title>\n<meta name=\"description\" content=\"Explore top emerging major depressive disorder therapies, breakthrough drugs, and market insights with DelveInsight.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"7 Emerging Major Depressive Disorder Drugs To Watch\" \/>\n<meta property=\"og:description\" content=\"Explore top emerging major depressive disorder therapies, breakthrough drugs, and market insights with DelveInsight.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-28T12:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T05:17:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162714\/04.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"7 Emerging Major Depressive Disorder Drugs To Watch","description":"Explore top emerging major depressive disorder therapies, breakthrough drugs, and market insights with DelveInsight.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch","og_locale":"en_US","og_type":"article","og_title":"7 Emerging Major Depressive Disorder Drugs To Watch","og_description":"Explore top emerging major depressive disorder therapies, breakthrough drugs, and market insights with DelveInsight.","og_url":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-02-28T12:00:00+00:00","article_modified_time":"2025-09-10T05:17:15+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162714\/04.jpg","type":"image\/jpeg"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch","url":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch","name":"7 Emerging Major Depressive Disorder Drugs To Watch","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162714\/04.jpg","datePublished":"2025-02-28T12:00:00+00:00","dateModified":"2025-09-10T05:17:15+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Explore top emerging major depressive disorder therapies, breakthrough drugs, and market insights with DelveInsight.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#faq-question-1757481400469"},{"@id":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#faq-question-1757481407220"},{"@id":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#faq-question-1757481421600"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162714\/04.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162714\/04.jpg","width":466,"height":284,"caption":"7 Game-Changing Major Depressive Disorder Drugs in Development"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#faq-question-1757481400469","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#faq-question-1757481400469","name":"What are the FDA-approved drugs for major depressive disorder available in the market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Currently, widely prescribed drugs for MDD include AbbVie and Gedeon Richter\u2019s VRAYLAR, Axsome Therapeutics\u2019 AUVELITY, Johnson &amp; Johnson\u2019s SPRAVATO, Otsuka\u2019s REXULTI, and others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#faq-question-1757481407220","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#faq-question-1757481407220","name":"Where is the major depressive disorder market headed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"In 2023, the major depressive disorder market across the 7MM was valued at an impressive USD 7.2 billion, and it\u2019s poised for even greater expansion, with exciting growth on the horizon through 2034.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#faq-question-1757481421600","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder-drugs-to-watch#faq-question-1757481421600","name":"What are the top 7 MDD drugs expected to change the market in the coming years?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The promising 7 MDD drugs in clinical trials include COMPASS Pathways\u2019 COMP360, SAGE Therapeutics and Biogen\u2019s Zuranolone, Luye Pharma\u2019s LY03005, Relmada Therapeutics\u2019 REL-1017, Minerva Neurosciences and Janssen Pharmaceutical\u2019s seltorexant, and BioLite and ABVC BioPharma\u2019s ABV-1504, among others.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/28162714\/04-300x183.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Major Depressive Disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Major Depressive Disorder (MDD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Major Depressive Disorder Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">major depressive disorder therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">major depressive disorder treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">MDD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Spravato<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Major Depressive Disorder<\/span>","<span class=\"advgb-post-tax-term\">Major Depressive Disorder (MDD)<\/span>","<span class=\"advgb-post-tax-term\">Major Depressive Disorder Market<\/span>","<span class=\"advgb-post-tax-term\">major depressive disorder therapies<\/span>","<span class=\"advgb-post-tax-term\">major depressive disorder treatment<\/span>","<span class=\"advgb-post-tax-term\">MDD<\/span>","<span class=\"advgb-post-tax-term\">Spravato<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 7 months ago"},"absolute_dates":{"created":"Posted on Feb 28, 2025","modified":"Updated on Sep 10, 2025"},"absolute_dates_time":{"created":"Posted on Feb 28, 2025 5:30 pm","modified":"Updated on Sep 10, 2025 10:47 am"},"featured_img_caption":"7 Game-Changing Major Depressive Disorder Drugs in Development","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31162"}],"version-history":[{"count":6,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31162\/revisions"}],"predecessor-version":[{"id":33323,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31162\/revisions\/33323"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31171"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31162"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31162"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}